Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short term Debt (2017 - 2025)

Historic Short term Debt for United Therapeutics (UTHR) over the last 6 years, with Q1 2025 value amounting to $200.0 million.

  • United Therapeutics' Short term Debt fell 5000.0% to $200.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $200.0 million, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $300.0 million for FY2024, which is 2500.0% down from last year.
  • Per United Therapeutics' latest filing, its Short term Debt stood at $200.0 million for Q1 2025, which was down 5000.0% from $300.0 million recorded in Q4 2024.
  • United Therapeutics' Short term Debt's 5-year high stood at $400.0 million during Q4 2023, with a 5-year trough of $200.0 million in Q1 2025.
  • Its 3-year average for Short term Debt is $342.9 million, with a median of $400.0 million in 2023.
  • Per our database at Business Quant, United Therapeutics' Short term Debt surged by 3333.33% in 2024 and then plummeted by 5000.0% in 2025.
  • United Therapeutics' Short term Debt (Quarter) stood at $400.0 million in 2023, then dropped by 25.0% to $300.0 million in 2024, then crashed by 33.33% to $200.0 million in 2025.
  • Its Short term Debt stands at $200.0 million for Q1 2025, versus $300.0 million for Q4 2024 and $400.0 million for Q3 2024.